Attenuation of biventricular pressure gradients by cibenzoline in an 18-year-old patient with hypertrophic obstructive cardiomyopathy

Circulation Journal

Volumn 66, Issue 12, 2002, Pages 1173-1175

  Hiasa, Go ^a   Hamada, Mareomi ^a   Shigematsu, Yuji ^a   Hara, Yuji ^a   Ohtsuka, Tomoaki ^a   Ogimoto, Akiyoshi ^a   Saeki, Hideyuki ^a   Suzuki, Jun ^a   Matsunaka, Tsuyoshi ^a   Hamada, Hironobu ^a   Okura, Takafumi ^a   Hiwada, Kunio ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biventricular hypertrophic obstructive cardiomyopathy; Cibenzoline; Pressure gradient

Indexed keywords

CIBENZOLINE; PROPRANOLOL; ANTIARRHYTHMIC AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AORTA SUBVALVULAR STENOSIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART MURMUR; HEART VENTRICLE PRESSURE; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; TREATMENT OUTCOME; ADOLESCENT; BLOOD PRESSURE; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART VENTRICLE FUNCTION; HYPERTROPHIC CARDIOMYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; SCINTISCANNING;

ADOLESCENT; ANTI-ARRHYTHMIA AGENTS; BLOOD PRESSURE; CARDIOMYOPATHY, HYPERTROPHIC; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMANS; IMIDAZOLES; MAGNETIC RESONANCE IMAGING; MALE; RADIONUCLIDE IMAGING; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION;

EID: 0036895576     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.66.1173     Document Type: Article

References (20)

1. Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis: Clinical analysis of 126 patients with emphasis on the natural history. Circulation 1968; 37: 759-788.
2. Maron BJ, Tajik AJ, Ruttenberg HD, Graham TP, Atwood GF, Victorica BE, et al. Hypertrophic cardiomyopathy in infants: Clinical features and natural history. Circulation 1982; 65: 7-17.
3. Maron BJ, McIntosh CL, Klues HG, Cannon RO III, Roberts WC. Morphologic basis for obstruction to right ventricular outflow in hypertrophic cardiomyopathy. Am J Cardiol 1993; 71: 1089-1094.
4. Morrow AG, Fisher RD, Fogarty TJ. Isolated hypertrophic obstruction to right ventricular outflow: Clinical, hemodynamic, and angiographic findings before and after operative treatment. Am Heart J 1969; 77: 814-817.
5. Tsuchihashi K, Tsuchida A, Hikita N, Yonekura S, Iwakura M, Hashimoto A, et al. Inspiratory right ventricular outflow obstruction in a patient with hypertrophic cardiomyopathy. Jpn Heart J 1988; 29: 871-875.
6. Hamada M, Shigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama K, et al. Class Ia antiarrhythmic drug cibenzoline: A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997; 96: 1520-1524.
7. Ohtsuka T, Hamada M, Hara Y, Kuwahara T, Kodama K, Shigematsu Y, et al. An early systolic sound associated with midventricular obstruction in a patient with hypertrophic cardiomyopathy. Jpn Circ J 1998; 62: 385-388.
8. Tokuyasu K, Hara Y, Matsumoto Y, Hashida H, Ikeda S, Ohtsuka T, et al. Hypertrophic cardiomyopathy with mid-ventricular obstruction and splenic infarction associated with paroxysmal atrial fibrillation: A case report. J Cardiol 1999; 34: 273-277.
9. Botti G, Tagliavini S, Bonatti V, Aurier E. Isolated hypertrophic obstructive cardiomyopathy of the right ventricle. G Ital Cardiol 1979; 9: 170-181.
10. Maron BJ, Lipson LC, Roberts WC, Savage DD, Epstein SE. 'Malignant' hypertrophic cardiomyopathy: Identification of a subgroup of families with unusually frequent premature death. Am J Cardiol 1978; 41: 1133-1140.
11. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: A profile of 78 patients. Circulation 1982; 65: 1388-1394.
12. Maron BJ, Fananapazir L. Sudden cardiac death in hypertrophic cardiomyopathy. Circulation 1992; 85(Suppl I): I-57-I-63.
13. Yoshida M, Nakamura Y, Fukuhara T, Higashikawa M, Okada M, Shichiri G, et al. Prognostic determinants of hypertrophic cardiomyopathy: The results of the Shiga Cardiomyopathy Study. Jpn Circ J 1995; 59: 745-753.
14. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655.
15. Schulte HD, Bircks WH, Loesse B, Godehardt EA, Schwartzkopff B, et al. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy: Late results up to twenty-five years. J Thorac Cardiovasc Surg 1993; 106: 709-717.
16. Fananapazir L, Cannon RO III, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms reflactory to verapamil and β-adrenergic blocker therapy. Circulation 1992; 85: 2149-2161.
17. Angelkov L, Trajic S, Popovic Z, Jovovic L, Bojic M, Popovic AD. Acute effects of DDD pacing in patients with pulmonary infundibular stenosis. Am J Cardiol 1999; 84: 117-118.
18. Sakai Y, Kawakami Y, Hirota Y, Ito T, Shimada S, Tokaji Y, et al. Dual-chamber pacing in hypertrophic obstructive cardiomyopathy: A comparison of acute and chronic effects. Jpn Circ J 1999; 63: 971-975.
19. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214.
20. Hamada M, Shigematsu Y, Hara Y, Suzuki M, Ohtsuka T, Hiasa G, et al. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Jpn Circ J 2001; 65: 531-538.